期刊
ONCOIMMUNOLOGY
卷 7, 期 12, 页码 -出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/2162402X.2018.1526250
关键词
Ampligen (R); bacillus Calmette-Guerin; Hiltonol (R); imiquimod; motolimod; SD-101
资金
- American Society for Blood and Marrow Transplantation (ASBMT) New Investigator Award
- Burroughs Wellcome Fund Postdoctoral Enrichment Program
- Damon Runyon Physician-Scientist Award
- Department of Radiation Oncology of Weill Cornell Medical College (New York, US)
Toll-like receptor (TLR) agonists demonstrate therapeutic promise as immunological adjuvants for anticancer immunotherapy. To date, three TLR agonists have been approved by US regulatory agencies for use in cancer patients. Additionally, the potential of hitherto experimental TLR ligands to mediate clinically useful immunostimulatory effects has been extensively investigated over the past few years. Here, we summarize recent preclinical and clinical advances in the development of TLR agonists for cancer therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据